凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
梅花生物(600873)公告正文

梅花集团:2012年半年度报告摘要

公告日期 2012-08-18
股票简称:梅花生物 股票代码:600873
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                    1
                            梅花生物科技集团股份有限公司
                                2012 年半年度报告摘要§1 重要提示1.1 本公司董事会、监事会及董事、监事、高级管理人员保证本报告所载资料不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
    本半年度报告摘要摘自半年度报告全文,投资者欲了解详细内容,应当仔细阅读半年度报告全文。1.2 公司全体董事出席董事会会议。1.3 公司半年度财务报告未经审计。1.4 是否存在被控股股东及其关联方非经营性占用资金情况?否1.5 是否存在违反规定决策程序对外提供担保的情况?否1.6 公司负责人孟庆山、主管会计工作负责人李勇刚及会计机构负责人(会计主管人员)陶忠声明:保证半年度报告中财务报告的真实、完整。§2 公司基本情况2.1 基本情况简介
         股票简称       梅花集团
         股票代码       600873
    股票上市交易所     上海证券交易所
                                    董事会秘书                            证券事务代表
         姓名           杨慧兴                                付晓丹
                        河北省廊坊市经济技术开发区华祥路      河北省廊坊市经济技术开发区华祥路 66
       联系地址
                        66 号                                 号
         电话           0316-2359652                          0316-2359652
         传真           0316-2359670                          0316-2359670
       电子信箱         yanghuixing@meihuagrp.com             fuxiaodan@meihuagrp.com2.2 主要财务数据和指标2.2.1 主要会计数据和财务指标
                                                                               单位:元 币种:人民币
                                                                               本报告期末比上年度期
                                  本报告期末               上年度期末
                                                                                     末增减(%)
    总资产                          14,317,401,644.78     13,840,835,835.01                       3.44
    所有者权益(或股东权益)         5,425,652,596.10      5,144,277,853.53                       5.47归属于上市公司股东的每股
                                               2.00                     1.90                   5.26净资产(元/股)
                                                                               本报告期比上年同期增
                               报告期(1-6 月)            上年同期
                                                                                       减(%)
    营业利润                           272,179,188.14          381,536,725.67                   -28.66
    利润总额                           364,816,157.62          490,616,824.90                   -25.64归属于上市公司股东的净利
                                    281,374,742.57          392,577,818.47                   -28.33润归属于上市公司股东的扣除
                                    202,616,495.93          300,046,653.49                   -32.47非经常性损益的净利润
    基本每股收益(元)                              0.10                     0.14                 -28.57第 1 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                                 2扣除非经常性损益后的基本
                                                    0.07                   0.11                     -36.36每股收益(元)
    稀释每股收益(元)                                   0.10                   0.14                      -28.57
    加权平均净资产收益率(%)                            5.32                   7.66          减少 2.34 个百分点经营活动产生的现金流量净
                                         536,009,225.65         -193,164,306.93                     377.49额每股经营活动产生的现金流
                                                    0.20                  -0.07                     377.49量净额(元)2.2.2 非经常性损益项目√适用 □不适用
                                                                                  单位:元 币种:人民币
                   非经常性损益项目                                               金额
    非流动资产处置损益                                                                          -1,914,439.80计入当期损益的政府补助,但与公司正常经营业务密切相
    关,符合国家政策规定、按照一定标准定额或定量持续享                                          94,573,314.00受的政府补助除外除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资产、交易性金融负债产生的公允价值变动损
                                                                                                259,558.84益,以及处置交易性金融资产、交易性金融负债和可供出售金融资产取得的投资收益
    除上述各项之外的其他营业外收入和支出                                                           -21,904.72
    所得税影响额                                                                               -14,138,281.68
                         合计                                                                78,758,246.64§3 股本变动及股东情况3.1 股份变动情况表√适用 □不适用
                                                                                                    单位:股
                   本次变动前                       本次变动增减(+,-)                    本次变动后
                                                  公
                                        发
                                                  积
                                比例    行   送                                                            比例
                   数量                           金        其他           小计              数量
                                (%)     新   股                                                            (%)
                                                  转
                                        股
                                                  股一、有限
                                                      -1,316,812,68   -1,316,812,68
    售条件股   2,417,500,800       89.26                                                    1,100,688,115     40.64
                                                                  5               5份1.其他内
            1,704,338,064       62.93                  -603,649,949    -603,649,949      1,100,688,115     40.64资持股
    境内自
            1,704,338,064       62.93                  -603,649,949    -603,649,949      1,100,688,115     40.64然人持股2.外资持
              713,162,736       26.33                  -713,162,736    -713,162,736                  0         0股境外法人
              713,162,736       26.33                  -713,162,736    -713,162,736                  0         0持股二、无限
    售条件流     290,735,803       10.74                 1,316,812,685   1,316,812,685      1,607,548,488     59.36通股份1.人民币
              290,735,803       10.74                 1,316,812,685   1,316,812,685      1,607,548,488     59.36普通股三、股份
            2,708,236,603         100                             0                 0    2,708,236,603       100总数第 2 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                                      33.2 股东数量和持股情况
                                                                                              单位:股
                          报告期末股东总数                                             74,738 户
                                                  前十名股东持股情况
                                  持股比例                     报告期内增    持有有限售条件股        质押或冻结的股
      股东名称       股东性质                   持股总数
                                    (%)                            减              份数量                份数量
                     境内自然
       孟庆山                       31.54      854,103,033          0          854,103,033           质押 210,000,000
                         人
                     境内自然
       胡继军                       13.64      369,394,122          0                  0             质押 310,000,000
                         人香港鼎晖生物科
                     境外法人       12.39      335,625,120     -27,000,000             0                  未知
    技有限公司新天域生化科技
                     境外法人       9.77       264,537,616     -86,000,000             0                  未知
    投资有限公司
                     境内自然
       杨维永                       2.91       78,810,526           0           78,810,526           质押 74,900,000
                         人
                     境内自然
       王爱军                       2.63       71,316,274           0           71,316,274           质押 71,316,274
                         人
                     境内自然
       李宝骏                       2.14       58,020,019           0                  0                   无
                         人
    山东五洲投资集      境内非国
                                    1.99       53,859,966           0                  0                  未知
    团有限公司          有法人
                     境内自然
       梁宇擘                       1.98       53,668,518           0                  0                   无
                         人
                     境内自然
       王洪山                       1.62       43,756,765           0           43,756,765                 无
                         人
                                             前十名无限售条件股东持股情况
                股东名称                持有无限售条件股份的数量                       股份种类及数量
                 胡继军                          369,394,122            人民币普通股           369,394,122
      香港鼎晖生物科技有限公司                   335,625,120            人民币普通股           335,625,120
    新天域生化科技投资有限公司                    264,537,616            人民币普通股           264,537,616
                 李宝骏                          58,020,019             人民币普通股               58,020,019
      山东五洲投资集团有限公司                   53,859,966             人民币普通股               53,859,966
                 梁宇擘                          53,668,518             人民币普通股               53,668,518
                 王加琪                          19,823,507             人民币普通股               19,823,507
                 郭振群                          19,340,006             人民币普通股               19,340,006
                 潘耀冬                          18,856,506             人民币普通股               18,856,506
                 王友山                          18,131,256             人民币普通股               18,131,256上述股东关联关系或一致行动的说
                                           前十大无限售条件股东之间未知其关联关系,也未知其一致行动人情况。
               明
    3.3    控股股东及实际控制人变更情况□适用 √不适用§4 董事、监事和高级管理人员情况第 3 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                               44.1 董事、监事和高级管理人员持股变动□适用 √不适用§5 董事会报告5.1 主营业务分行业、产品情况表
                                                                                          单位:元 币种:人民币
                                                                        营业收入比   营业成本比
    分行业或分                                              营业利润率                               营业利润率比上
                       营业收入           营业成本                      上年同期增   上年同期增
    产品                                                    (%)                                  年同期增减(%)
                                                                          减(%)      减(%)分行业
                                                                                                    减少 6.08 个百
    生物发酵       2,546,105,131.70      2,044,695,291.26        19.69          26.33        36.68
                                                                                                              分点
                                                                                                  减少 13.56 个百
    氨基酸              976,328,299.00     742,646,182.84        23.93          67.37       103.66
                                                                                                              分点
                                                                                                    增加 9.00 个百
    肥料                116,721,929.79      93,744,548.15        19.69         -13.59       -22.29
                                                                                                              分点
                                                                                                    增加 9.27 个百
    化工                128,846,450.65      95,766,997.08        25.67         -30.57       -38.27
                                                                                                              分点分产品
    味精及谷氨                                                                                         减少 9.39 个百
                2,055,956,425.41      1,669,072,145.75        18.82          26.81        43.39
    酸                                                                                                           分点
                                                                                                  减少 13.56 个百
    氨基酸产品          976,328,299.00     742,646,182.84        23.93          67.37       103.66
                                                                                                              分点
                                                                                                    增加 9.00 个百
    有机肥              116,721,929.79      93,744,548.15        19.69         -13.59       -22.29
                                                                                                              分点
                                                                                                    减少 0.02 个百
    硫酸                             0                  0              0      -100.00      -100.00
                                                                                                              分点
                                                                                                    增加 6.39 个百
    淀粉附产品          389,770,081.57     332,598,307.19        14.67          18.64        10.38
                                                                                                              分点
                                                                                                  减少 22.60 个百
    液氨                128,846,450.65      95,766,997.08        25.67         104.51       193.86
                                                                                                              分点
    菌体蛋白及                                                                                         增加 3.91 个百
                     100,378,624.72      43,024,838.32        57.14          53.14        40.35
    其它                                                                                                         分点5.2 主营业务分地区情况
                                                                                          单位:元 币种:人民币
              地区                           营业收入                          营业收入比上年增减(%)
    国内                                            2,961,522,840.12                                           32.50
    国外                                              806,478,971.02                                           17.845.3 主营业务及其结构发生重大变化的原因说明□适用 √不适用5.4 主营业务盈利能力(毛利率)与上年相比发生重大变化的原因说明□适用 √不适用5.5 利润构成与上年度相比发生重大变化的原因分析□适用 √不适用5.6 募集资金使用情况5.6.1 募集资金运用□适用 √不适用第 4 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                             55.6.2 变更项目情况□适用 √不适用5.7 非募集资金项目情况
    报告期内,公司无非募集资金投资项目。5.8 董事会下半年的经营计划修改计划□适用 √不适用5.9 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生大幅度变动的警示及说明□适用 √不适用5.10 公司董事会对会计师事务所本报告期“非标准审计报告”的说明□适用 √不适用5.11 公司董事会对会计师事务所上年度“非标准审计报告”涉及事项的变化及处理情况的说明□适用 √不适用§6 重要事项6.1 收购资产
    □适用   √不适用6.2 出售资产
    □适用   √不适用6.3 担保事项
    √适用   □不适用
                                                                            单位:元 币种:人民币
                                      公司对控股子公司的担保情况
    报告期内对子公司担保发生额合计                                                 1,050,914,866.88
    报告期末对子公司担保余额合计                                                   2,438,180,002.00
                               公司担保总额情况(包括对控股子公司的担保)
    担保总额                                                                       2,438,180,002.00
    担保总额占公司净资产的比例(%)                                                             44.94其中:
    上述三项担保金额合计                                                           2,438,180,002.006.4 关联债权债务往来
    □适用   √不适用6.5 重大诉讼仲裁事项
    √适用   □不适用
    截止本报告期末,与公司有关的诉讼共有 6 宗:(1)陈素诉四川五洲明珠置业有限公司、梅花集团、四川金沱置地有限公司、成都喜玛拉雅大酒店有限公司借款纠纷案2011 年 3 月 28 日,陈素向成都市中级人民法院提交《民事起诉状》,其诉讼请求为:①请求判令四川五洲明珠置业有限公司(以下简称"五洲置业")偿付原告借款本金人民币 590 万元及违约金和利息第 5 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                             6500 万元;②请求判令梅花集团、四川金沱置地有限公司(以下简称"金沱置地")、成都喜玛拉雅大酒店有限公司(以下简称"喜玛拉雅酒店")共同承担连带赔偿责任;③请求判令四被告承担诉讼及财产保全费用。《民事起诉状》提出的事实与理由为:原告于 2009 年 10 月 15 日、2010 年 3 月 15 日分别向五洲置业提供借款 420 万元、170 万元,借款到期后,五洲置业没有履行还款义务。五洲置业于 2007 年 11 月 20 日成立,注册资本为 5,000 万元,股东为五洲明珠(现已更名为梅花生物科技集团有限公司,即本公司)、金沱置地和成都酒店。原告陈素认为,五洲明珠和喜玛拉雅酒店未按照规定缴纳出资;2010 年 6 月,五洲置地未通知原告而将喜玛拉雅酒店和五洲明珠认缴的注册资本全部减去,导致原告陈素债权不能实现;五洲明珠、金沱置地和喜玛拉雅酒店作为五洲置地的股东,应该承担连带清偿责任。2011 年 12 月 26 日,经四川省成都市中级人民法院(2011)成民初字第 420 号民事判决书判决如下:五洲置业向原告支付借款本金 370 万元,并同时支付相应的利息。喜玛拉雅酒店和本公司在未出资本息范围内,对五洲置业不能清偿的部分承担补充赔偿责任,金沱置业承担连带责任。截止本报告期末,此案正在二审受理中。(2)张治民诉四川五洲明珠置业有限公司、梅花集团、四川金沱置地有限公司、成都喜玛拉雅大酒店有限公司借款纠纷案2011 年 3 月 28 日,张治民向成都市中级人民法院提交《民事起诉状》,其诉讼请求为:①请求判令五洲置业偿付原告借款本金人民币 1,226 万元及利息 294 万元;②请求判令梅花集团、金沱置地、喜玛拉雅酒店共同承担连带赔偿责任;③请求判令四被告承担诉讼及财产保全费用。第二次开庭审理时,原告变更诉讼请求为:①请求判令五州置业归还本金 400 万元及利息 300 万元;②请求判令梅花集团、金沱置地、喜玛拉雅酒店共同承担连带赔偿责任。《民事起诉状》提出的事实与理由为:原告于 2008 年 7 月至 2008 年 8 月期间共向五洲置业累计提供借款 400 万元,除了 2009 年 2 月 15 日之前归还了 70 万元利息后,五洲置业再没有履行还款义务。五洲置业于 2007 年 11 月 20 日成立,注册资本为 5,000 万元,股东为五洲明珠(现在更名为梅花生物科技集团股份有限公司,即本公司)、金沱置地和喜玛拉雅酒店。原告认为,五洲明珠和喜玛拉雅酒店未按照规定缴纳出资;2010 年 6 月,五洲置地未通知原告而将喜玛拉雅酒店和五洲明珠认缴的注册资本全部减去,导致原告陈素债权不能实现;五洲明珠、金沱置地和喜玛拉雅酒店作为五洲置地的股东,应该承担连带清偿责任。2011 年 12 月 26 日,经四川省成都市中级人民法院(2011)成民初字第 419 号民事判决书判决如下:五洲置业向原告支付借款本金 400 万元,并同时支付相应的利息。喜玛拉雅酒店和本公司在未出资本息范围内,对五洲置业不能清偿的部分承担补充赔偿责任,金沱置业承担连带责任。截止本报告期末,此案正在二审受理中。(3)张世龙诉成都喜玛拉雅大酒店有限公司、梅花集团股权转让纠纷案2011 年 9 月 9 日,张世龙向成都市中级人民法院提交《民事诉状》,其诉讼请求为:①判令被告喜玛拉雅酒店向原告支付五洲置业对原告所负债务 1,080 万元;②判令被告喜玛拉雅酒店赔偿原告投资损失 330 万元以及可得利益 1,000 万;承担违约金 218 万元;③判令被告梅花集团对上述债务承担无限连带保证责任;④判令二被告全额承担本案诉讼费用。《民事诉状》提出的事实与理由为:原告张世龙于 2010 年 12 月 22 日与金沱置地签订协议,受让后者持有的五洲置业 30%的股权以及对五洲置业享有的债权,五洲置业向原告确认五洲置业欠金沱置地第 6 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                            71,080 万元,金沱置地持有的五洲置地的出资额为 300 万元。同日,喜玛拉雅酒店向原告承诺,清偿五洲置业对原告所负债务、保证原告收回投资及分红利润 1,000 万元以及相应的违约责任等。同时,梅花集团对喜玛拉雅酒店的承诺提供无限连带责任保证。2011 年 2 月,原告对五洲置业增加 30 万元投资。后喜玛拉雅酒店违反承诺,原告要求两被告履行相关义务。2012 年 7 月 13 日,四川省成都市中级人民法院出具(2011)成民初字第 1102 号判决书判决如下:①喜马拉雅酒店于判决发生法律效力之日起十日内向原告张世龙支付五洲置业对原告所负债务 1080 万元;②喜马拉雅酒店与判决发生法律效力之日起十日内向原告赔偿投资损失 300 万元;③喜马拉雅酒店于判决发生法律效力之日起十日内向原告支付违约金 150 万元;④被告梅花集团对喜马拉雅酒店的前述给付义务承担连带责任。(4)周乐园诉四川五洲明珠置业有限公司、梅花集团借款纠纷案2011 年 9 月 1 日,周乐园向成都市金牛区人民法院提交《民事诉状》,其诉讼请求为:①判令被告立即归还借款 160 万元;②判令被告支付违约金 4,800 元;③判令被告按月息 3%向原告支付利息直至判决之日止(从 2009 年 9 月 15 日至 2011 年 8 月 31 日利息为 112.8 万元);④被告承担本案的律师代理费 16 万元和全部诉讼费用。《民事诉状》提出的事实与理由为:原告于 2009 年 2 月 15 日,原告与五洲置业、五洲明珠(现更名为梅花生物科技集团股份有限公司,即本公司)签订《担保借款协议书》,约定原告向五洲置业提供借款 160 万元,借款期限 90 天,如到期未还,按照千分之三支付违约金,同时从违约的次日起按月息3%向原告支付利息,五洲明珠对此承担保证责任。借款到期后,五洲置业没有履行还款义务。原告要求两被告履行还款义务。本公司收到成都市金牛区人民法院送达的《应诉通知书》、《民事起诉状副本》等诉讼文书后,已经委托山东诚公律师事务所积极应诉。截至本报告期末,该案件正在审理之中。(5)李柏平诉四川五洲明珠置业有限公司、成都喜马拉雅大酒店有限公司、梅花集团民间借贷纠纷案2012 年 4 月 5 日,李柏平向成都市金牛区人民法院提交《民事起诉状》,其诉讼请求为:①判令第一被告偿还借款人民币 200 万元及自 2008 年 3 月 19 日起按银行同期贷款利率向原告支付资金利息至清偿时为止约 2 万元,以上合计 202 万元;②判令第二、第三对本诉讼中第一项诉求在未交清注册资本金范围内承担连带赔偿责任;③本案的诉讼相关费用由三被告共同承担。《民事起诉状》提出的事实与理由为:第一被告四川五洲明珠置业有限公司于 2008 年 3 月 19 日向原告借款 200 万元至今未偿还。第一被告于 2007 年 11 月 20 日成立,注册资本为 5,000 万元,第二、第三被告作为第一被告的股东,没有全面履行出资义务,应当在未交清注册资本的范围内承担连带赔偿责任。公司收到成都市金牛区人民法院送达的《应诉通知书》、《民事起诉状副本》等诉讼文书后,已经委托山东诚公律师事务所积极应诉。截至本报告期末,该案件正在审理之中。(6)四川宏大建筑工程有限公司诉四川五洲明珠置业有限公司、成都喜马拉雅大酒店有限公司、梅花集团、四川金沱置地有限公司建筑合同纠纷案2012 年 4 月 5 日,四川宏大建筑工程有限公司向成都市金牛区人民法院提交《民事起诉状》,其诉讼请求:①判令第一被告赔偿各项损失 380 万元、违约金 114 万元及约定向原告履行支付义务时其按银行同期贷款利率向原告支付占用资金利息至履行给付义务时为止约 8 万元,以上合计 502 万元;②判令第二、第三对本诉讼中第一项诉求在未交清注册资本金范围内承担连带赔偿责任及担保责任,第四被告承担连带赔偿责任;③本案的诉讼相关费用由被告共同承担。第 7 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                            8《民事起诉状》提出的事实与理由为:第一被告于 2007 年 11 月设立,第二、三、四被告均为股东。2007 年初,原告拟承包第一被告待开发的五洲圣雅商住大厦工程,因第二被告是第一被告的大股东,所以原告在 2007 年 3、4 月份,分别以成都市龙泉驿区第一建筑工程公司及自己的名义分三次向第二被告共缴纳了投标保证金和工程保证金 300 万元。2008 年 7 月 ,原告与第一被告就承包"加洲梦想-五洲圣雅商住大厦"签订了《建筑工程施工合同》,因该项目未如期开工,经双方协商,原告与第一被告签订《违约赔偿承诺书》,第二、三被告作为担保人在《违约赔偿承诺书》签字盖章,但第一被告未按《违约赔偿承诺书》履行赔偿义务。第一被告设立时,第二、三被告未全面履行出资义务,应当在各自未出资的本息范围内对第一被告的债务承担赔偿责任,第四被告作为第一被告的发起人应对第二、三被告承担连带责任,第二、三被告在《违约赔偿承诺书》上以担保人的名义签字盖章,还应承担担保责任。公司收到成都市金牛区人民法院送达的《应诉通知书》、《民事起诉状副本》等诉讼文书后,已经委托山东诚公律师事务所积极应诉。截止本报告期末,该案件正在审理之中。
    上述 6 宗尚未了结的诉讼,均系前次重大资产重组交割日前发生的事项。根据公司与前次重大资产重组实施前的控股股东五洲集团于 2009 年 4 月 27 日签订的《资产出售协议》,在交割日前与五洲明珠有关的任何争议、诉讼事项、或有责任相关的所有责任、损失、风险及债务、开支及税费均由五洲集团承担。
    前次重大资产重组实施前的控股股东五洲集团针对上述 6 宗尚未了结的诉讼分别出具了承诺函:确认上述诉讼发生的费用及因诉讼给公司带来的损失由五洲集团承担。6.6 其他重大事项及其影响和解决方案的分析说明6.6.1 证券投资情况
    □适用      √不适用6.6.2 持有其他上市公司股权情况
    □适用      √不适用6.6.3 持有非上市金融企业股权情况
    √适用      □不适用
                                       占该公司                              报告期所
    所持对     最初投资成    持有数量                期末账面价值    报告期损              会计核算
                                       股权比例                              有者权益              股份来源
    象名称       本(元)      (股)                    (元)      益(元)                科目
                                         (%)                               变动(元)西藏银
    行股份                                                                                 长期股权
            45,000,000   45,000,000           3   45,000,000.00          0          0              自有资金
    有限公                                                                                 投资司
    合计     45,000,000   45,000,000       /          45,000,000          0          0      /          /§7 财务会计报告7.1 审计意见
    财务报告                 √未经审计                        □审计7.2 财务报表第 8 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                              9
                                      合并资产负债表
                                     2012 年 6 月 30 日编制单位:梅花生物科技集团股份有限公司
                                                                         单位:元 币种:人民币
            项目                  附注                 期末余额             年初余额流动资产:
    货币资金                注释(一)                 746,091,669.41       1,862,868,600.12
    结算备付金
    拆出资金
    交易性金融资产
    应收票据                注释(二)                 145,750,741.12          54,719,220.00
    应收账款                注释(三)                 267,140,930.58         245,099,721.97
    预付款项                注释(四)               2,378,338,692.08       1,826,380,874.46
    应收保费
    应收分保账款
    应收分保合同准备金
    应收利息
    应收股利
    其他应收款              注释(五)                  52,286,891.58          51,096,929.99
    买入返售金融资产
    存货                    注释(六)               1,251,175,000.74       1,238,421,023.13
    一年内到期的非流动资产
    其他流动资产
       流动资产合计                                   4,840,783,925.51       5,278,586,369.67非流动资产:
    发放委托贷款及垫款
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资            注释(七)                 149,858,633.40         148,956,018.85
    投资性房地产
    固定资产                注释(八)               5,938,919,349.42       6,142,508,095.94
    在建工程                注释(九)               2,433,504,497.82       1,306,954,507.51
    工程物资                注释(十)                 125,810,872.98         124,797,797.68
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                注释(十一)               803,151,009.50         813,379,442.76
    开发支出
    商誉                    注释(十二)                18,079,863.29          18,079,863.29
    长期待摊费用
    递延所得税资产          注释(十三)                 7,293,492.86           7,573,739.31
    其他非流动资产
       非流动资产合计                                 9,476,617,719.27       8,562,249,465.34
          资产总计                                   14,317,401,644.78      13,840,835,835.01流动负债:
    短期借款                注释(十五)             3,569,184,747.94       4,260,003,491.63
    向中央银行借款
    吸收存款及同业存放
    拆入资金
    交易性金融负债
    应付票据                注释(十六)               348,950,000.00         315,650,000.00
    应付账款                注释(十七)               789,749,238.59         686,636,541.98
    预收款项                注释(十八)               164,460,818.99         196,190,935.80第 9 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                     10
      卖出回购金融资产款
      应付手续费及佣金
      应付职工薪酬            注释(十九)               29,922,606.72              38,805,490.11
      应交税费                注释(二十)             -511,676,070.18            -434,752,747.34
      应付利息                注释(二十一)             83,713,340.91              82,901,085.19
      应付股利
      其他应付款              注释(二十二)            238,151,360.41             202,611,521.71
      应付分保账款
      保险合同准备金
      代理买卖证券款
      代理承销证券款
      一年内到期的非流动负债
    其他流动负债
        流动负债合计                                  4,712,456,043.38           5,348,046,319.08非流动负债:
    长期借款                 注释(二十三)          2,260,000,000.00           2,320,000,000.00
    应付债券                 注释(二十四)          1,884,794,319.30             990,311,662.40
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债           注释(二十五)             34,498,686.00              38,200,000.00
        非流动负债合计                                4,179,293,005.30           3,348,511,662.40
          负债合计                                    8,891,749,048.68           8,696,557,981.48所有者权益(或股东权益):
    实收资本(或股本)       注释(二十六)          2,708,236,603.00           2,708,236,603.00
    资本公积                 注释(二十七)            187,528,409.88             187,528,409.88
    减:库存股
    专项储备
    盈余公积                 注释(二十八)            128,335,925.96             128,335,925.96
    一般风险准备
    未分配利润               注释(二十九)          2,401,551,657.26           2,120,176,914.69
    外币报表折算差额
    归属于母公司所有者权
                                                      5,425,652,596.10           5,144,277,853.53益合计
    少数股东权益
          所有者权益合计                              5,425,652,596.10           5,144,277,853.53
        负债和所有者权益总
                                                     14,317,401,644.78          13,840,835,835.01计
    法定代表人:孟庆山            主管会计工作负责人:李勇刚                 会计机构负责人:陶忠
                                   母公司资产负债表
                                     2012 年 6 月 30 日编制单位:梅花生物科技集团股份有限公司
                                                                                单位:元 币种:人民币
            项目                附注                 期末余额                      年初余额流动资产:
    货币资金                                             65,383,979.93               992,270,244.25
    交易性金融资产
    应收票据                                                583,676.00                22,883,450.00
    应收账款                 注释(一)                  87,959,241.56               139,432,742.38
    预付款项                                             13,500,089.39               224,799,167.86
    应收利息第 10 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                         11
      应收股利                                         400,000,000.00     400,000,000.00
      其他应收款              注释(二)             4,571,020,489.73   3,307,900,198.45
      存货                                              49,258,669.05      86,526,972.03
      一年内到期的非流动资产
    其他流动资产
       流动资产合计                                  5,187,706,145.66   5,173,812,774.97非流动资产:
    可供出售金融资产
    持有至到期投资
    长期应收款
    长期股权投资             注释(三)             2,889,858,633.40   2,638,956,018.85
    投资性房地产
    固定资产                                          820,143,170.31   1,038,225,491.60
    在建工程                                           46,008,707.19      67,505,341.08
    工程物资                                                                   2,271.72
    固定资产清理
    生产性生物资产
    油气资产
    无形资产                                           98,164,432.37     100,203,803.67
    开发支出
    商誉
    长期待摊费用
    递延所得税资产                                         12,607.07           8,774.68
    其他非流动资产
       非流动资产合计                                3,854,187,550.34   3,844,901,701.60
          资产总计                                   9,041,893,696.00   9,018,714,476.57流动负债:
    短期借款                                        1,920,000,000.00   2,456,953,552.66
    交易性金融负债
    应付票据
    应付账款                                           32,128,798.35     289,486,477.08
    预收款项                                            4,588,870.70      17,703,208.59
    应付职工薪酬                                        1,774,383.88       7,713,444.31
    应交税费                                           -3,987,277.97      -4,944,280.85
    应付利息                                           82,409,418.92      79,830,833.32
    应付股利
    其他应付款                                        117,813,248.58      38,437,903.60
    一年内到期的非流动负债
    其他流动负债
       流动负债合计                                  2,154,727,442.46   2,885,181,138.71非流动负债:
    长期借款                                        1,500,000,000.00   1,500,000,000.00
    应付债券                                        1,884,794,319.30     990,311,662.40
    长期应付款
    专项应付款
    预计负债
    递延所得税负债
    其他非流动负债
       非流动负债合计                                3,384,794,319.30   2,490,311,662.40
          负债合计                                   5,539,521,761.76   5,375,492,801.11所有者权益(或股东权益):
    实收资本(或股本)                              2,708,236,603.00   2,708,236,603.00
    资本公积                                          155,744,114.24     155,744,114.24
    减:库存股第 11 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                     12
    专项储备
    盈余公积                                             128,335,925.96              128,335,925.96
    一般风险准备
    未分配利润                                           510,055,291.04              650,905,032.26所有者权益(或股东权益)合
                                                        3,502,371,934.24            3,643,221,675.46计
       负债和所有者权益(或
                                                        9,041,893,696.00            9,018,714,476.57股东权益)总计
    法定代表人:孟庆山            主管会计工作负责人:李勇刚                   会计机构负责人:陶忠
                                               合并利润表
                                             2012 年 1—6 月
                                                                                单位:元 币种:人民币
                    项目                     附注              本期金额               上期金额
    一、营业总收入                                              3,787,574,916.79       2,939,314,990.41
                                           注释(三
    其中:营业收入                                          3,787,574,916.79       2,939,314,990.41
                                           十)
           利息收入
           已赚保费
           手续费及佣金收入
    二、营业总成本                                              3,516,557,902.04       2,557,994,704.02
                                           注释(三
    其中:营业成本                                          2,985,540,805.49       2,144,787,785.36
                                           十)
            利息支出
            手续费及佣金支出
            退保金
            赔付支出净额
            提取保险合同准备金净额
            保单红利支出
            分保费用
                                           注释(三十
            营业税金及附加                                       8,024,727.46          12,537,506.94
                                           一)
                                           注释(三十
            销售费用                                           170,067,139.37         149,957,967.65
                                           二)
                                           注释(三十
            管理费用                                           181,910,887.85         151,208,831.69
                                           二)
                                           注释(三十
            财务费用                                           169,172,515.53          91,055,962.61
                                           二)
                                           注释(三十
            资产减值损失                                         1,841,826.34           8,446,649.77
                                           三)
    加:公允价值变动收益(损失以“-”号填列)
                                           注释(三十
       投资收益(损失以“-”号填列)                            1,162,173.39             216,439.28
                                           四)
          其中:对联营企业和合营企业的投
                                                                   902,614.55             -71,971.67资收益
       汇兑收益(损失以“-”号填列)
    三、营业利润(亏损以“-”号填列)                            272,179,188.14         381,536,725.67
                                           注释(三十
    加:营业外收入                                             95,537,862.37         110,505,548.28
                                           五)
                                           注释(三十
    减:营业外支出                                              2,900,892.89           1,425,449.05
                                           六)
       其中:非流动资产处置损失                                  2,660,024.79             680,015.02
    四、利润总额(亏损总额以“-”号填列)                        364,816,157.62         490,616,824.90
    减:所得税费用                        注释(三十           83,441,415.05          98,039,006.43第 12 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                     13
                                           七)
    五、净利润(净亏损以“-”号填列)                            281,374,742.57        392,577,818.47
    归属于母公司所有者的净利润                                281,374,742.57        392,577,818.47
    少数股东损益六、每股收益:
    (一)基本每股收益                                                  0.10                  0.14
    (二)稀释每股收益                                                  0.10                  0.14七、其他综合收益
    八、综合收益总额                                              281,374,742.57        392,577,818.47
    归属于母公司所有者的综合收益总额                          281,374,742.57        392,577,818.47
    归属于少数股东的综合收益总额
    法定代表人:孟庆山            主管会计工作负责人:李勇刚                 会计机构负责人:陶忠
                                              母公司利润表
                                             2012 年 1—6 月
                                                                                单位:元 币种:人民币
                    项目                     附注          本期金额                  上期金额
    一、营业收入                              注释(四)      345,810,405.47            967,301,372.00
    减:营业成本                          注释(四)      358,856,562.07            912,544,713.50
          营业税金及附加                                        726,810.62              2,422,779.12
          销售费用                                              224,178.93              3,473,731.95
          管理费用                                           56,483,440.74             69,722,760.19
          财务费用                                           68,697,179.90             45,278,606.95
          资产减值损失                                          321,669.31             -4,989,023.80
    加:公允价值变动收益(损失以“-”号填列)
          投资收益(损失以“-”号填列)   注释(五)              911,306.21            103,479.71
            其中:对联营企业和合营企业的
                                                                   902,614.55            -71,232.59投资收益
    二、营业利润(亏损以“-”号填列)                        -138,588,129.89           -61,048,716.20
    加:营业外收入                                             367,435.51             5,242,818.71
    减:营业外支出                                             938,598.28             1,215,825.10
          其中:非流动资产处置损失                              819,268.28               471,391.09
    三、利润总额(亏损总额以“-”号填列)                    -139,159,292.66           -57,021,722.59
    减:所得税费用                                           1,690,448.56             5,113,669.53
    四、净利润(净亏损以“-”号填列)                        -140,849,741.22           -62,135,392.12五、每股收益:
    (一)基本每股收益
    (二)稀释每股收益六、其他综合收益
    七、综合收益总额                                          -140,849,741.22           -62,135,392.12
    法定代表人:孟庆山           主管会计工作负责人:李勇刚               会计机构负责人:陶忠第 13 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                  14
                                            合并现金流量表
                                            2012 年 1—6 月
                                                                             单位:元 币种:人民币
            项目                 附注                本期金额                   上期金额一、经营活动产生的现金流量:
      销售商品、提供劳务收到
                                                       3,892,234,421.82          3,020,721,290.43的现金
      客户存款和同业存放款项净增加额
      向中央银行借款净增加额
      向其他金融机构拆入资金净增加额
      收到原保险合同保费取得的现金
      收到再保险业务现金净额
      保户储金及投资款净增加额
      处置交易性金融资产净增加额
      收取利息、手续费及佣金的现金
      拆入资金净增加额
      回购业务资金净增加额
      收到的税费返还                                            203,016.88           9,982,532.51
      收到其他与经营活动有     注释(三十
                                                         117,763,337.80            115,257,153.10
    关的现金                      八)
        经营活动现金流入小
                                                       4,010,200,776.50          3,145,960,976.04计
      购买商品、接受劳务支付
                                                       2,669,626,864.16          2,588,931,949.95的现金
      客户贷款及垫款净增加额
      存放中央银行和同业款项净增加额
      支付原保险合同赔付款项的现金
      支付利息、手续费及佣金的现金
      支付保单红利的现金
      支付给职工以及为职工
                                                         232,632,762.38            168,712,433.08支付的现金
      支付的各项税费                                     360,684,199.76            366,976,537.35
      支付其他与经营活动有     注释(三十
                                                         211,247,724.55            214,504,362.59
    关的现金                      八)
        经营活动现金流出小
                                                       3,474,191,550.85          3,339,125,282.97计
          经营活动产生的现
                                                         536,009,225.65           -193,164,306.93金流量净额二、投资活动产生的现金流量:
      收回投资收到的现金                                                             1,200,000.00
      取得投资收益收到的现
                                                                259,558.84             288,410.95金
      处置固定资产、无形资产                               2,959,104.53                 44,451.00第 14 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                   15和其他长期资产收回的现金净额
      处置子公司及其他营业单位收到的现金净额
      收到其他与投资活动有关的现金
        投资活动现金流入小
                                                          3,218,663.37                1,532,861.95计
      购建固定资产、无形资产
                                                      1,425,221,312.13            1,259,941,868.53和其他长期资产支付的现金
      投资支付的现金                                                                  4,500,000.00
      质押贷款净增加额
      取得子公司及其他营业单位支付的现金净额
      支付其他与投资活动有关的现金
        投资活动现金流出小
                                                      1,425,221,312.13            1,264,441,868.53计
          投资活动产生的现
                                                     -1,422,002,648.76           -1,262,909,006.58金流量净额三、筹资活动产生的现金流量:
      吸收投资收到的现金
      其中:子公司吸收少数股东投资收到的现金
      取得借款收到的现金                              2,379,067,815.23            3,185,632,827.59
      发行债券收到的现金
      收到其他与筹资活动有     注释(三十
                                                         53,659,349.99              160,000,000.00
    关的现金                      八)
        筹资活动现金流入小
                                                      2,432,727,165.22            3,345,632,827.59计
      偿还债务支付的现金                              2,357,914,286.02              803,015,072.92
      分配股利、利润或偿付利
                                                        253,169,586.29              574,636,435.45息支付的现金
      其中:子公司支付给少数股东的股利、利润
      支付其他与筹资活动有     注释(三十
                                                          2,700,000.00               95,801,838.84
    关的现金                      八)
        筹资活动现金流出小
                                                      2,613,783,872.31            1,473,453,347.21计
          筹资活动产生的现
                                                       -181,056,707.09            1,872,179,480.38金流量净额四、汇率变动对现金及现金等
                                                          3,942,403.15               -1,185,396.79价物的影响五、现金及现金等价物净增加
                                                     -1,063,107,727.05              414,920,770.08额
      加:期初现金及现金等价
                                                      1,652,684,850.59            1,005,526,344.64物余额六、期末现金及现金等价物余
                                                        589,577,123.54            1,420,447,114.72额
    法定代表人:孟庆山             主管会计工作负责人:李勇刚                会计机构负责人:陶忠第 15 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                 16
                                             母公司现金流量表
                                               2012 年 1—6 月
                                                                             单位:元 币种:人民币
                项目                  附注           本期金额                  上期金额一、经营活动产生的现金流量:
    销售商品、提供劳务收到的现金                           376,870,952.10          1,271,755,367.42
      收到的税费返还                                        203,016.88              9,982,532.51
    收到其他与经营活动有关的现金                         2,996,484,121.47            914,704,700.74
        经营活动现金流入小计                          3,373,558,090.45          2,196,442,600.67
      购买商品、接受劳务支付的现金                      356,269,310.92          1,600,031,333.98
    支付给职工以及为职工支付的现金                          43,172,877.46             58,217,817.47
      支付的各项税费                                     17,805,743.97             39,273,570.43
      支付其他与经营活动有关的现
                                                      2,587,862,620.75          1,100,072,846.85金
        经营活动现金流出小计                          3,005,110,553.10          2,797,595,568.73
          经营活动产生的现金流量
                                                        368,447,537.35           -601,152,968.06净额二、投资活动产生的现金流量:
      收回投资收到的现金
      取得投资收益收到的现金                                    8,691.66          600,174,712.30
      处置固定资产、无形资产和其他
                                                         36,044,216.36长期资产收回的现金净额
      处置子公司及其他营业单位收到的现金净额
      收到其他与投资活动有关的现金
        投资活动现金流入小计                             36,052,908.02            600,174,712.30
      购建固定资产、无形资产和其他
                                                          9,822,321.59             39,952,716.04长期资产支付的现金
      投资支付的现金                                     79,760,337.38            334,500,000.00
      取得子公司及其他营业单位支付的现金净额支付其他与投资活动有关的现金
        投资活动现金流出小计                             89,582,658.97            374,452,716.04
    投资活动产生的现金流量净额                             -53,529,750.95            225,721,996.26三、筹资活动产生的现金流量:
      吸收投资收到的现金
      取得借款收到的现金                              1,720,000,000.00          2,210,000,000.00
      发行债券收到的现金
      收到其他与筹资活动有关的现
                                                      1,658,906,255.25            498,748,989.28金
        筹资活动现金流入小计                          3,378,906,255.25          2,708,748,989.28
      偿还债务支付的现金                              1,320,000,000.00            110,000,000.00
      分配股利、利润或偿付利息支付
                                                        174,604,051.13            539,137,870.11的现金
    支付其他与筹资活动有关的现金                         3,087,200,000.00          1,699,506,849.23
        筹资活动现金流出小计                          4,581,804,051.13          2,348,644,719.34
    筹资活动产生的现金流量净额                          -1,202,897,795.88            360,104,269.94四、汇率变动对现金及现金等价物
                                                                    0.41           -1,047,538.12的影响
    五、现金及现金等价物净增加额                          -887,980,009.07            -16,374,239.98
      加:期初现金及现金等价物余额                      953,363,989.00            521,540,434.41
    六、期末现金及现金等价物余额                            65,383,979.93            505,166,194.43
    法定代表人:孟庆山                   主管会计工作负责人:李勇刚            会计机构负责人:陶忠第 16 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                                                                               17
                                                                       合并所有者权益变动表
                                                                         2012 年 1—6 月                                单位:元 币种:人民币
                                                                                            本期金额
            项目                                                         归属于母公司所有者权益                                          少
                                                                                                                                         数    所有者权益合计
                                实收资本(或股本)       资本公积      减:库存  专项       盈余公积      一般      未分配利润      其
                                                                         股      储备                                                    股
                                                                                                          风险                      他
    一、上年年末余额                2,708,236,603.00      187,528,409.88                     128,335,925.96          2,120,176,914.69        东   5,144,277,853.53
                                                                                                          准
      加:会计政策变更                                                                                                                   权
                                                                                                          备
                                                                                                                                         益
         前期差错更正
         其他
    二、本年年初余额                2,708,236,603.00      187,528,409.88                     128,335,925.96          2,120,176,914.69             5,144,277,853.53
    三、本期增减变动金额(减少以                                                                                      281,374,742.57               281,374,742.57“-”号填列)
    (一)净利润                                                                                                      281,374,742.57               281,374,742.57(二)其他综合收益
    上述(一)和(二)小计                                                                                            281,374,742.57               281,374,742.57(三)所有者投入和减少资本1.所有者投入资本2.股份支付计入所有者权益的金额3.其他(四)利润分配1.提取盈余公积2.提取一般风险准备3.对所有者(或股东)的分配4.其他(五)所有者权益内部结转1.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
    四、本期期末余额                2,708,236,603.00       187,528,409.88                    128,335,925.96         2,401,551,657.26              5,425,652,596.10
    法定代表人:孟庆山                                   主管会计工作负责人:李勇刚                           会计机构负责人:陶忠第 17 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                                                                             18
                                                                    合并所有者权益变动表
                                                                                                                                 单位:元 币种:人民币
                                                                                            上年同期金额
    项目                                                                     归属于母公司所有者权益                                       少
                                                                             减: 专 项               一 般                      其   数    所有者权益合计
                                   实收资本(或股本)   资本公积             库存 储备   盈余公积     风 险   未分配利润              股
                                                                                                                                 他
                                                                                                                                      东
    一、上年年末余额                   1,008,236,603.00     1,887,528,409.88     股
                                                                                         104,079,070 准备     1,929,050,178.35        权    4,928,894,261.29
    加:会计政策变更                                                                         .06                                          益前期差错更正
           其他
    二、本年年初余额                   1,008,236,603.00     1,887,528,409.88                104,079,070           1,929,050,178.35              4,928,894,261.29
    三、本期增减变动金额(减少以“-”                                                      .06
    号填列)                                                                                                      -111,540,483.03               -111,540,483.03
    (一)净利润                                                                                                  392,577,818.47                392,577,818.47(二)其他综合收益
    上述(一)和(二)小计                                                                                        392,577,818.47                392,577,818.47(三)所有者投入和减少资本1.所有者投入资本2.股份支付计入所有者权益的金额3.其他
    (四)利润分配                                                                                                -504,118,301.50               -504,118,301.501.提取盈余公积2.提取一般风险准备
    3.对所有者(或股东)的分配                                                                                   -504,118,301.50               -504,118,301.504.其他(五)所有者权益内部结转1.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
    四、本期期末余额                   1,008,236,603.00     1,887,528,409.88                104,079,070           1,817,509,695.32              4,817,353,778.26
    法定代表人:孟庆山                             主管会计工作负责人:李勇刚               .06                    会计机构负责人:陶忠第 18 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                                                                             19
                                                                  母公司所有者权益变动表
                                                                        2012 年 1—6 月                                         单位:元 币种:人民币
                                                                                              本期金额
    项目                                                                                专项储                    一般风险
                                 实收资本(或股本)    资本公积         减:库存股            盈余公积                    未分配利润        所有者权益合计
                                                                                     备                        准备
    一、上年年末余额                2,708,236,603.00      155,744,114.24                         128,335,925.96              650,905,032.26    3,643,221,675.46
    加:会计政策变更
         前期差错更正
         其他
    二、本年年初余额                2,708,236,603.00      155,744,114.24                         128,335,925.96              650,905,032.26    3,643,221,675.46三、本期增减变动金额(减少以
    “-”号填列)                                                                                                           -140,849,741.22   -140,849,741.22
    (一)净利润                                                                                                             -140,849,741.22   -140,849,741.22(二)其他综合收益
    上述(一)和(二)小计                                                                                                   -140,849,741.22   -140,849,741.22(三)所有者投入和减少资本1.所有者投入资本2.股份支付计入所有者权益的金额3.其他(四)利润分配1.提取盈余公积2.提取一般风险准备3.对所有者(或股东)的分配4.其他(五)所有者权益内部结转1.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
    四、本期期末余额                2,708,236,603.00      155,744,114.24                         128,335,925.96              510,055,291.04    3,502,371,934.24
    法定代表人:孟庆山                                    主管会计工作负责人:李勇刚                                          会计机构负责人:陶忠第 19 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                                                                                       20
                                                                       母公司所有者权益变动表
                                                                                                                                              单位:元 币种:人民币
                                                                                                  上年同期金额
               项目
                                      实收资本(或股本)      资本公积        减:库存   专项储备      盈余公积      一般风险准备     未分配利润      所有者权益合计
                                                                                股
    一、上年年末余额                     1,008,236,603.00     1,855,744,114.24                         104,079,070.06                   936,711,630.66   3,904,771,417.96
    加:会计政策变更
         前期差错更正
         其他
    二、本年年初余额                     1,008,236,603.00     1,855,744,114.24                       104,079,070.06                     936,711,630.66   3,904,771,417.96三、本期增减变动金额(减少以“-”
    号填列)                                                                                                                           -566,253,693.62    -566,253,693.62
    (一)净利润                                                                                                                        -62,135,392.12     -62,135,392.12(二)其他综合收益
    上述(一)和(二)小计                                                                                                              -62,135,392.12     -62,135,392.12(三)所有者投入和减少资本1.所有者投入资本2.股份支付计入所有者权益的金额3.其他
    (四)利润分配                                                                                                                     -504,118,301.50    -504,118,301.501.提取盈余公积2.提取一般风险准备
    3.对所有者(或股东)的分配                                                                                                        -504,118,301.50    -504,118,301.504.其他(五)所有者权益内部结转1.资本公积转增资本(或股本)2.盈余公积转增资本(或股本)3.盈余公积弥补亏损4.其他(六)专项储备1.本期提取2.本期使用(七)其他
    四、本期期末余额                     1,008,236,603.00     1,855,744,114.24                       104,079,070.06                     370,457,937.04   3,338,517,724.34
    法定代表人:孟庆山                                             主管会计工作负责人:李勇刚                                           会计机构负责人:陶忠第 20 页 共 21 页
    梅花生物科技集团股份有限公司 2012 年半年度报告摘要                                                 217.3本报告期无会计政策、会计估计的变更。7.4 本报告期无前期会计差错更正。7.5 企业合并及合并财务报表7.5.1 合并范围发生变更的说明与上年相比本年新增合并单位 1 家:廊坊梅花调味食品有限公司。廊坊梅花调味食品有限公司是本年新设立的全资子公司。7.5.2 本期新纳入合并范围的主体和本期不再纳入合并范围的主体7.5.2.1 本期新纳入合并范围的子公司、特殊目的主体、通过受托经营或承租等方式形成控制权的经营实体
                                                                              单位:元 币种:人民币
                 名称                           期末净资产                      本期净利润
    廊坊梅花调味食品有限公司                             243,184,382.60                    -6,815,617.40
                                                                                    董事长:孟庆山
                                                                                ___________________
                                                                       梅花生物科技集团股份有限公司
                                                                                   2012 年 8 月 17 日第 21 页 共 21 页
数据加载中...
prevnext
手机查看股票